Zelluna Elevates Manufacturing Lead to CTO Amid Clinical Trial Push
Event summary
- Emilie Gauthy promoted to CTO of Zelluna ASA effective February 3, 2026
- Gauthy led manufacturing and CMC development since joining in 2022
- Zelluna submitted Clinical Trial Application for ZI-MA4-1 to UK MHRA in December 2025
- First-in-human clinical data for ZI-MA4-1 expected mid-2026
- GMP clinical batch produced and quality-tested under Gauthy's leadership
The big picture
This promotion reflects Zelluna's strategic focus on scaling its manufacturing capabilities to support multiple clinical programs. The move comes as the company prepares to enter the competitive space of solid tumor cell therapies, where manufacturing efficiency and regulatory approval timelines will be critical differentiators. With initial clinical data expected mid-2026, the company's ability to demonstrate both safety and efficacy will be key to attracting partners and investors.
What we're watching
- Clinical Development
- How quickly Zelluna can translate its manufacturing capabilities into positive clinical data for ZI-MA4-1
- Pipeline Expansion
- Whether Gauthy's CMC foundation can support the development of additional TCR-NK therapies beyond ZI-MA4-1
- Regulatory Progress
- The pace at which UK MHRA reviews and potentially approves Zelluna's clinical trial applications
Related topics